

MULTIDISCIPLINARY THORACIC CANCERS SYMPOSIUM



FAIRMONT SCOTTSDALE PRINCESS | SCOTTSDALE, ARIZONA | DECEMBER 2-4, 2021

Poster Viewing & Research Feature Presentations

First thing to remember: NO PAPER POSTERS!

We are excited to introduce digital posters at the 2021 Multidisciplinary Thoracic Cancers Symposium. This new format will provide greater viewing capabilities as well as improved networking. Below is helpful information about this new format.

- All digital posters will be available to view on touchscreen screens.
- Posters are accessible online in addition to digital poster viewing stations in the Exhibit Hall. Posters are searchable by topic/track, presenter name, or poster number.
- Oral poster presentation sessions, which we are calling “Research Features”, will take place throughout the Symposium. See below for more information.

POSTER BUILDER

- The Poster Builder can be accessed through the [Speaker Center](#) in the “My Presentations” tab. All formatting requirements are pre-set, so it’s easy to cut and paste your information into the template.
- There is a \$70 fee per poster for digital upload, payable at the time of upload. The fee has been set at a price that is substantially lower than traditional paper printing, and we are confident that this new format will provide greater visibility of every poster than the previous paper format.
- The deadline to upload your poster is **Monday, November 22**.

FORMATTING

- Please use the [Symposium template](#) provided (also available in the Speaker Center and on the Poster Builder site). You can adjust the boxes to accommodate your data, move fields around, add your institution, etc. All sections will zoom in when you touch them on the screen.
- Be sure to review the proof that our vendor, Multilearning, sends you. When you review your poster, you will be able to see how the system works.
- We prefer that you not change the conference background color.
- All posters will have a QR code that will link to the presenter’s email (unless you opted out when you logged on to the Poster Builder).

CHECKING-IN

- When you arrive at the Fairmont Scottsdale Princess, you can go to the Registration Desk to pick up your badge. The staff there will also be able to answer any questions you might have. Registration is located in the East Foyer, and the hours are as follows:
 - Wednesday, December 1, 4:00 pm – 6:00 pm MT
 - Thursday, December 2, 7:00 am – 4:15 pm MT
 - Friday, December 3, 7:00 am – 5:00 pm MT
 - Saturday, December 4, 7:00 am – 12:15 pm MT

MULTIDISCIPLINARY THORACIC CANCERS SYMPOSIUM



FAIRMONT SCOTTSDALE PRINCESS | SCOTTSDALE, ARIZONA | DECEMBER 2-4, 2021

RESEARCH FEATURE

- The Research Feature sessions are comprised of oral poster presentations. Research Feature presenters will have five minutes to discuss their poster and three minutes for questions and answers. Three sessions have been scheduled throughout the Symposium:
 - Thursday, December 2, 2021: 2:45 PM - 3:15 PM
 - Friday, December 3, 2021: 9:30 AM - 10:00 AM
 - Friday, December 3, 2021: 2:15 PM - 2:45 PM
- Research Features will take place in the Exhibit Hall (Salons F-I of the Princess Ballroom).
- All presenters should arrive at their designated station 15 minutes before the scheduled session start time. Please view the Research Feature Schedule section on the following pages to see when you are presenting and at what station.
- All stations are touchscreen; presenters can touch to zoom into different sections of their poster.
- We encourage you to PRACTICE your presentation to make sure the talk fits into the five-minute talk window. A three-minute question and answer will occur directly following each presentation.
- Below is an example of the presentation home screen listing presenting authors and abstract titles for that station:

Welcome to the

16 15 h

E-Poster Session

CNS ePoster Discussion 1 - Brain Metastases

Discussant: Shannon Fogh - Kevin Oh

Mudit Chowdhary
1000 – Post-Treatment Neutrophil-to-Lymphocyte Ratio as a Predictor of Overall Survival

Paul Sperduto
1001 – Prognostic Factors in Patients with Renal Cell Carcinoma and Brain Metastases

Michael Soike
1002 – Initial Brain Metastasis Velocity, Does the Rate at Which Cancers First Seed the Brain Predict Survival?

Yazid Belkacemi
1003 – Discrepancies between biological markers of primary breast cancer and their brain metastases

Yao Yu
1004 – Refining Estimates of Local Failure and Adverse Radiation Effect for Brain Metastases

Shireen Parsai
1005 – Optimizing Intracranial Disease Control for Breast Cancer Patients with HER2

Jason Chan
1006 – Implications of HER2 status on local control and adverse radiation effects after whole brain radiotherapy

Samuel Marcrom
1007 – Focal Management of Large Brain Metastases and Risk of Leptomeningeal Disease

Rohan Katipally
1008 – Surgical Resection and Posterior Fossa Location Increase the Incidence of Leptomeningeal Disease

- When finished with your presentation, click “Browse ePosters” on bottom right of screen (see below) and it will return to the home screen. The next presenter will tap their name/abstract title to open his/her poster.

MULTIDISCIPLINARY THORACIC CANCERS SYMPOSIUM



FAIRMONT SCOTTSDALE PRINCESS | SCOTTSDALE, ARIZONA | DECEMBER 2-4, 2021

RESEARCH FEATURE SCHEDULE

Research Feature 1: Thursday, December 2, 2021: 2:45 PM - 3:15 PM

Screen 1				
Times	Title	#	Presenter	Category
2:45 p.m. – 2:53 p.m.	Effect of Antibiotic Therapy on Immunotherapy Outcomes for Non-Small Cell Lung Cancer: Analysis from the Veterans Health Administration	100	William Stokes	Immunotherapy
2:53 p.m. – 3:01 p.m.	Plasma cell-free RNA PD-L1 Expression and Clinical Outcomes with Immunotherapy	101	Paul Walker	Immunotherapy
3:01 p.m. – 3:15 p.m.	Open Q&A			

Screen 2				
Times	Title	#	Presenter	Category
2:45 p.m. – 2:53 p.m.	DREAM3R: DuRvalumab with chEmotherapy as first line treatment in advanced pleural Mesothelioma A phase 3 Randomised trial	102	Patrick Forde	Mesothelioma, Thymic Malignancies, Carcinoid Tumors and Other Thoracic Malignancies
2:53 p.m. – 3:01 p.m.	Salvage Radiosurgery for Recurrent Cardiac Sarcoma: A Case Report	103	Sunjay Arvind Shah	Mesothelioma, Thymic Malignancies, Carcinoid Tumors and Other Thoracic Malignancies
3:01 p.m. – 3:15 p.m.	Open Q&A			

Screen 3				
Times	Title	#	Presenter	Category
2:45 p.m. – 2:53 p.m.	METex14 ctDNA dynamics & resistance mechanisms detected in liquid biopsy (LBx) from patients (pts) with METex14 skipping NSCLC treated with tepotinib	110	Richard O'Hara	Non-small Cell Lung Cancer: Metastatic
2:53 p.m. – 3:01 p.m.	Upfront Treatment with Osimertinib versus Osimertinib and Radiotherapy for Patients with EGFR-positive Non-small Cell Lung Cancer Brain Metastases	111	Ammoren Dohm	Non-small Cell Lung Cancer: Metastatic
3:01 p.m. – 3:09 p.m.	Intracranial activity of tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC enrolled in VISION	112	Christine Bestvina	Non-small Cell Lung Cancer: Metastatic
3:09 p.m. – 3:15 p.m.	Open Q&A			

MULTIDISCIPLINARY
THORACIC CANCERS
SYMPOSIUM



FAIRMONT SCOTTSDALE PRINCESS | SCOTTSDALE, ARIZONA | DECEMBER 2-4, 2021

Research Feature 2: Friday, December 3, 2021: 9:30 AM - 10:00 AM

Screen 1				
Times	Title	#	Presenter	Category
9:30 a.m. – 9:38 a.m.	Surgical Outcomes for Early-Stage Non-Small Cell Lung Cancer at Facilities with Stereotactic Body Radiation Therapy Programs	104	Yusuf Syed	Non-small Cell Lung Cancer: Early-stage
9:38 a.m. – 9:47 a.m.	Accounting for Operability Status in Retrospective Comparisons of Surgery vs SBRT for Early-Stage NSCLC	105	Joshua Lorenz	Non-small Cell Lung Cancer: Early-stage
9:47 a.m. – 10:00 a.m.	Open Q&A			

Screen 2				
Times	Title	#	Presenter	Category
9:30 a.m. – 9:38 a.m.	Prediction of Regional and Distant Failure after Definitive Thoracic Stereotactic Body Radiation Therapy (SBRT) using Pre-treatment CT-based Radiomic Analysis	106	Ewa Zabrocka	Non-small Cell Lung Cancer: Early-stage
9:38 a.m. – 9:46 a.m.	Dosimetric Comparison of Arms Up Versus Arms Down Positions for Lung SBRT	107	Todd Carpenter	Non-small Cell Lung Cancer: Early-stage
9:46 a.m. – 9:54 a.m.	Comparing Clinicopathologic Factors and Survival in Stage III Adenocarcinoma and Squamous Cell Carcinoma of the Lung Following Definitive Chemoradiotherapy	108	Stephen Abel	Non-small Cell Lung Cancer: Locally Advanced
9:54 a.m. – 10:00 a.m.	Open Q&A			

Screen 3				
Times	Title	#	Presenter	Category
9:30 a.m. – 9:38 a.m.	IGNYTE: A Phase 1/2 Multi-cohort Clinical Trial of RP1 ± Nivolumab in Patients with Non-small Cell Lung Cancer and Other Solid Tumors	109	Hamid Emamekhoo	Non-small Cell Lung Cancer: Locally Advanced
9:38 a.m. – 9:46 a.m.	A multi-center, open-label, randomized, two-arm study, to evaluate the efficacy of Osimertinib with early intervention SRS treatment compared to the continuation of Osimertinib alone, in patients with EGFR-mutated NSCLC and asymptomatic brain metastases	113	Philip Blumenfeld	Novel Therapeutics/Targeted Agents
9:46 a.m. – 9:54 a.m.	Racial Disparities in Treatment and Outcome of Non-Small Cell Lung Cancer (NSCLC) Patients Across Different Facility Types	114	Fan Zhu	Outcomes/Health Services Research
9:54 a.m. – 10:00 a.m.	Open Q&A			

MULTIDISCIPLINARY
THORACIC CANCERS
SYMPOSIUM



FAIRMONT SCOTTSDALE PRINCESS | SCOTTSDALE, ARIZONA | DECEMBER 2-4, 2021

Research Feature 3: Friday, December 3, 2021: 2:15 PM - 2:45 PM

Screen 1				
Times	Title	#	Presenter	Category
2:15 p.m. – 2:23 p.m.	A comparison of overall patient reported distress levels in Appalachian cancer patients from economically distressed versus non-economically distressed counties receiving radiation therapy for thoracic malignancies	115	Robert Miller	Outcomes/Health Services Research
2:23 p.m. – 2:31 p.m.	Implementation of standardized lecture to improve radiation oncology knowledge in multidisciplinary lung cancer care team: initial results of a multi-institutional pilot study	116	Jason Ye	Outcomes/Health Services Research
2:31 p.m. – 2:45 p.m.	Open Q&A			

Screen 2				
Times	Title	#	Presenter	Category
2:15 p.m. – 2:23 p.m.	Impact of Radiation Therapy on Inpatient Outcomes among Patients with Lung Cancer	117	Chanshyam Mudigonda	Outcomes/Health Services Research
2:23 p.m. – 2:31 p.m.	Sarcoidosis or sarcoid reaction with lung cancer in ethnic Han Chinese patients: a single center experience and literature review	118	Xian He	Outcomes/Health Services Research
2:31 p.m. – 2:39 p.m.	Indirect Treatment Comparison of Lurbinectedin vs Other Second-line Treatments for Small-cell Lung Cancer	119	Badri Rengarajan	Small Cell Lung Cancer
2:39 p.m. – 2:45 p.m.	Open Q&A			

Screen 3				
Times	Title	#	Presenter	Category
2:15 p.m. – 2:23 p.m.	End of Life Care in Hospitalized Patients with Lung Cancer	120	Tyiesha Brown	Supportive Care/Palliation/Nursing
2:23 p.m. – 2:31 p.m.	Comprehensive Analyses Identify a Signature Based on Pyroptosis-related Genes for Breast Cancer	121	Ying Zhou	Tumor Genomics/Precision Medicine
2:31 p.m. – 2:39 p.m.	Tumor Agnostic Models for NSCLC Drug Development	122	Priya Hays	Tumor Genomics/Precision Medicine
2:39 p.m. – 2:45 p.m.	Open Q&A			

MULTIDISCIPLINARY
THORACIC CANCERS
SYMPOSIUM



FAIRMONT SCOTTSDALE PRINCESS | SCOTTSDALE, ARIZONA | DECEMBER 2-4, 2021

QUESTIONS?

For any additional questions about the session format, please email: specialtymeetings@astro.org
For technical questions about poster upload, please email: support@multi posters.com